•Transpeptidase design: Completed de novo design for a listed pharmaceutical company, obtaining 82 new sequences with higher activity than natural enzymes in one round of validation.

•CALB industrial enzyme modification: The designed sequence enzyme activity is 1.7 times that of the wild type, significantly improving catalytic efficiency.

•eAgo gene-editing enzyme optimization: The enzyme maintains activity even after a 108-amino acid backbone reduction; three candidate sequences have been tested in wet experiments.